Cannabis use and cardiovascular, renal, and mortality outcomes in patients with type 2 diabetes receiving GLP-1 receptor agonists: A propensity score-matched cohort study
{{output}}
Background: Cannabis use is rising among adults with type 2 diabetes mellitus (T2DM). Whether cannabis use modifies the cardio-renal benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is unknown. ... ...
